Intervention

Pemetrexed

ClinicalTrials.gov intervention label

Clinical trials475

Recruiting82

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCNCT07586202 · 2026-07-28

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680 · 2026-07-27

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)NCT07642024 · 2026-07-24

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817 · 2026-06-04

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerNCT07662395 · 2026-05-09

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast CancerNCT06462092 · 2026-01-01

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782 · 2025-11-24

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung CancerNCT07381829 · 2025-10-27

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · 2025-10-24

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCNCT07178795 · 2025-09-29

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.NCT06296745 · 2025-09-01

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerNCT07122687 · 2025-08-26

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)NCT07070440 · 2025-07-16

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCNCT06745882 · 2025-06-13

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCNCT06364917 · 2025-05-30

AK129 Combination Therapy for Advanced Solid TumorsNCT06943820 · 2025-05-21

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCNCT06969612 · 2025-05-15

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsNCT06829459 · 2025-04-03

BBO-11818 in Adult Subjects With KRAS Mutant CancerNCT06917079 · 2025-03-31

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI TherapyNCT06868836 · 2025-03-30

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)NCT06731907 · 2025-03-30

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）NCT06927986 · 2025-03-30

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced MalignanciesNCT06839105 · 2025-02-21

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCNCT06754644 · 2025-01-15

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic PatientsNCT06576635 · 2024-12-16

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLCNCT06663306 · 2024-12-09

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · 2024-10-04

A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685 · 2024-09-19

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationNCT06416410 · 2024-08-07

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLCNCT05805631 · 2024-08-01

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · 2024-07-19

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerNCT06431685 · 2024-04-25

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung CancerNCT06304441 · 2024-04-18

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06236438 · 2024-04-10

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)NCT06312137 · 2024-04-03

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 · 2024-01-18

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya ReservoirNCT06399926 · 2023-10-30

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaNCT06057935 · 2023-09-21

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) NegativeNCT06001151 · 2023-08-07

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationNCT05789082 · 2023-06-20

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerNCT05501665 · 2023-05-09

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLCNCT05800340 · 2023-04-04

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung CancerNCT05766800 · 2023-03-14

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256 · 2023-03-01

Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · 2023-02-22

Common conditions

Leading sponsors

Eli Lilly and Company41 Merck Sharp & Dohme LLC25 AstraZeneca20 Bristol-Myers Squibb20 Hoffmann-La Roche19 M.D. Anderson Cancer Center9 National Cancer Institute (NCI)9 Memorial Sloan Kettering Cancer Center7 Novartis Pharmaceuticals7 SCRI Development Innovations, LLC7 Incyte Corporation6 Intergroupe Francophone de Cancerologie Thoracique6 Janssen Research & Development, LLC6 Tianjin Medical University Cancer Institute and Hospital6 AbbVie5

Trial status mix

COMPLETED167

RECRUITING82

TERMINATED74

ACTIVE_NOT_RECRUITING64

UNKNOWN45

WITHDRAWN24

NOT_YET_RECRUITING17

ENROLLING_BY_INVITATION1

SUSPENDED1

Phase mix

PHASE2257

PHASE3143

PHASE1104

PHASE48

NA7

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.